Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
China · Delayed Price · Currency is CNY 9.91
+0.19 (1.95%)
Sep 30, 2026, 3:04 PM CST
SHE:002728 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 5,061 | 5,417 | 4,457 | 6,511 | 4,998 | 3,794 | |
Market Cap Growth | 19.07% | 21.54% | -31.55% | 30.26% | 31.73% | 56.81% |
Enterprise Value | 4,929 | 5,362 | 4,497 | 6,483 | 5,397 | 4,334 |
Last Close Price | 9.91 | 10.65 | 8.74 | 12.05 | 10.56 | 7.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 70.53 | 66.33 | 217.47 | 25.72 | 28.05 | 29.90 |
Forward PE | - | 26.46 | 14.16 | - | - | - |
PS Ratio | 6.12 | 5.86 | 6.48 | 6.10 | 5.64 | 5.01 |
PB Ratio | 2.84 | 2.97 | 2.53 | 3.24 | 3.56 | 3.01 |
P/TBV Ratio | 4.49 | 4.66 | 4.02 | 4.89 | 7.07 | 6.75 |
P/FCF Ratio | 46.05 | 32.92 | - | 57.87 | 17.76 | 25.77 |
P/OCF Ratio | 27.62 | 22.19 | - | 32.79 | 13.45 | 14.78 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.96 | 5.80 | 6.54 | 6.08 | 6.09 | 5.72 |
EV/EBITDA Ratio | 33.65 | 35.59 | 47.44 | 17.71 | 19.95 | 18.96 |
EV/EBIT Ratio | 66.58 | 66.34 | 147.80 | 21.18 | 24.76 | 24.44 |
EV/FCF Ratio | 44.85 | 32.59 | - | 57.62 | 19.18 | 29.44 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.24 | 0.14 | 0.29 | 0.15 | 0.60 | 0.53 |
Debt / EBITDA Ratio | 2.90 | 1.75 | 5.44 | 0.84 | 3.13 | 2.90 |
Debt / FCF Ratio | 3.86 | 1.60 | - | 2.72 | 3.01 | 4.50 |
Net Debt / Equity Ratio | -0.07 | -0.04 | 0.03 | -0.17 | 0.08 | 0.23 |
Net Debt / EBITDA Ratio | -0.90 | -0.48 | 0.62 | -0.93 | 0.40 | 1.27 |
Net Debt / FCF Ratio | -1.20 | -0.44 | -0.43 | -3.03 | 0.38 | 1.97 |
Asset Turnover | 0.35 | 0.39 | 0.28 | 0.42 | 0.38 | 0.35 |
Inventory Turnover | 1.42 | 1.68 | 1.44 | 1.95 | 2.24 | 1.83 |
Quick Ratio | 1.11 | 1.30 | 1.13 | 1.76 | 0.80 | 1.01 |
Current Ratio | 1.59 | 1.89 | 1.60 | 2.37 | 1.02 | 1.43 |
Return on Equity (ROE) | 4.21% | 4.55% | 1.09% | 14.83% | 13.38% | 10.84% |
Return on Assets (ROA) | 1.96% | 2.14% | 0.77% | 7.56% | 5.91% | 5.13% |
Return on Invested Capital (ROIC) | 4.23% | 4.49% | 1.62% | 16.63% | 12.92% | 9.87% |
Return on Capital Employed (ROCE) | 4.10% | 4.40% | 1.70% | 15.00% | 15.20% | 11.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.48% | 1.51% | 0.46% | 3.89% | 3.56% | 3.35% |
FCF Yield | 2.17% | 3.04% | -3.05% | 1.73% | 5.63% | 3.88% |
Dividend Yield | 1.51% | 1.41% | 0.57% | 2.96% | 3.14% | 4.34% |
Payout Ratio | 135.08% | 30.50% | 889.52% | 58.86% | 82.84% | 109.03% |
Buyback Yield / Dilution | -10.63% | 0.38% | -11.31% | -5.16% | -9.09% | -2.75% |
Total Shareholder Return | -9.12% | 1.79% | -10.74% | -2.20% | -5.95% | 1.59% |